Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.78% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIK · Sep 30, 2025
Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001171843-25-007032General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
24.70% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-28.22% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
58.54% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
56.02% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-11.62% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
24.97% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 5.20%
- Current
- 6.78%
- Delta
- 1.58%
- Previous
- -0.67%
- Current
- 24.70%
- Delta
- 25.37%
- Previous
- -32.69%
- Current
- -28.22%
- Delta
- 4.47%
- Previous
- 59.97%
- Current
- 58.54%
- Delta
- -1.43%
- Previous
- 50.90%
- Current
- 56.02%
- Delta
- 5.12%
- Previous
- -14.81%
- Current
- -11.62%
- Delta
- 3.19%
- Previous
- 22.37%
- Current
- 24.97%
- Delta
- 2.60%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_INCREASED →Transitioned To · ANIK CASH_GENERATION_INCREASED →Transitioned To · ANIK GROWTH_INCREASED →Transitioned To · ANIK INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIK MARGIN_INCREASED →Transitioned To · ANIK PROFITABILITY_INCREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.